Multiple Sclerosis Clinical Trial
— VigiP-SEPOfficial title:
Impact of E-reporting by Patients With Relapsing-remitting Multiple Sclerosis on the Reporting of Adverse Drug Reactions in France: a Randomized Controlled Trial.
NCT number | NCT03029897 |
Other study ID # | 16-135 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 5, 2017 |
Est. completion date | April 24, 2019 |
Verified date | April 2018 |
Source | University Hospital, Caen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Adverse drug reactions are collected exhaustively during the experimental development phase
of the drug, but the trial population is not representative. In post-marketing authorization,
the use in the real life of medicines requires to specify the profile of adverse effects
through pharmacovigilance. However, in clinical practice, under-reporting of adverse drug
reactions prevents a satisfactory knowledge of the risks. For example, in the multiple
sclerosis (MS) patients population in 2015, only 1 case of congestive flushing was reported
by physicians, none by patients, for approximately 7,800 patients treated with Tecfidera®
dimethyl-fumarate, while trials reported 39% of flush.
The investigators propose a study measuring the impact of the deployment of e-reporting to
patients in a population suffering from multiple sclerosis in initiation of first line drug
therapy. The study design will be a randomized controlled trial. Twenty-four direct or
indirect partner centers of the OFSEP will be randomized in 2 arms (1 standard arm without
intervention, and one interventional arm), Each arm including 6 CHU, 3 CHG and 3 liberal
neurologists. CHUs will include 10 patients in 6 months, and CHGs and liberal neurologists 5
patients, a total of 180 patients will be included. The expected duration of this study is 12
months, 6 months of inclusion of patients, and one 6-month follow-up period for each patient.
At 1 month (+/- 15 days) of the follow-up period of each patient, a questionnaire will be
made by telephone call to each patient.
The study is part of the pharmacovigilance system in place in France and aims to improve its
efficiency by increasing declarations and therefore earlier detection of signals in order to
prevent and minimize risks.
The comparison of the two arms should make it possible to decide on the usefulness of
national support for e-reporting, while respecting a good integration with the French
pharmacovigilance system.
Status | Completed |
Enrollment | 161 |
Est. completion date | April 24, 2019 |
Est. primary completion date | April 24, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patient (> 18 years) with relapsing-remitting multiple sclerosis. Initiation of treatment of 1st line: interferon ß, peginterferon ß, glatiramer acetate, teriflunomide, dimethyl-fumarate. Exclusion Criteria: Patient with progressively progressive secondary or multiple sclerosis. Patient suffering from multiple sclerosis not treated with a first line treatment. |
Country | Name | City | State |
---|---|---|---|
France | CHU Caen | Caen |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Caen |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | number of reports of adverse drug reactions | number of reports of adverse drug reactions per patient in the intervention arm using mobile versus standard arm. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |